DV
Dividend Vision

RLAY — Relay Therapeutics, Inc.

Relay Therapeutics, Inc. (RLAY)

Total return is -43.3% over the past 6.1 years, 206.1 points behind SPY at 162.8%. Its deepest 1-year drawdown was 28.2%.

This is a single-stock equity holding in Relay Therapeutics, Inc., a biopharmaceutical company. The holding generates no dividend distributions, making it unsuitable for income-focused investors seeking regular payouts. It appeals primarily to growth-oriented investors seeking exposure to the biotech sector rather than those prioritizing dividend yield.

RLAY key facts

Asset type
Stock
Asset class
Equity
Inception date
07/16/2020
Distribution frequency
None
Last close
$19.86
Market cap
$4,352,153,088
Average volume
1530273.0
Beta
1.704
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.55